Attention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder that can persist into adulthood, although diagnosis and treatment initiation can occur at any age. Data suggest that diagnosis and drug-treatment rates among adults have historically lagged behind those of pediatric patients, but growing awareness of ADHD as an adult disorder—influenced, in part, by updated diagnostic criteria—has, in recent years, fueled greater industry focus on treating adult patients. Psychostimulants, nonstimulants, and amphetamines are key therapies for this population. This study uses national patient-level claims data to determine the prescribing patterns of drugs for adult patients with ADHD.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Takeda, Arbor Pharmaceuticals, Tris Pharma, Adlon Therapeutics, Ironshore Pharmaceuticals
Key drugs: Mydayis, Vyvanse, Jornay PM, Adhansia XR
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.